Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
IOVA Iovance Biotherapeutics, Inc. daily Stock Chart
IOVA [NASD]
Iovance Biotherapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.59 Insider Own0.20% Shs Outstand125.72M Perf Week-9.64%
Market Cap3.65B Forward P/E- EPS next Y-2.05 Insider Trans0.00% Shs Float116.26M Perf Month-20.12%
Income-197.60M PEG- EPS next Q-0.52 Inst Own- Short Float9.96% Perf Quarter13.78%
Sales- P/S- EPS this Y-25.10% Inst Trans0.06% Short Ratio6.09 Perf Half Y49.33%
Book/sh2.37 P/B12.26 EPS next Y-14.30% ROA-48.20% Target Price29.38 Perf Year136.64%
Cash/sh2.44 P/C11.90 EPS next 5Y- ROE-53.20% 52W Range9.82 - 38.92 Perf YTD4.99%
Dividend- P/FCF- EPS past 5Y-27.00% ROI- 52W High-25.33% Beta1.35
Dividend %- Quick Ratio8.10 Sales past 5Y- Gross Margin- 52W Low195.93% ATR3.64
Employees148 Current Ratio8.10 Sales Q/Q- Oper. Margin- RSI (14)51.83 Volatility8.60% 14.95%
OptionableYes Debt/Eq0.00 EPS Q/Q-84.30% Profit Margin- Rel Volume0.49 Prev Close28.88
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 AMC Payout- Avg Volume1.90M Price29.06
Recom1.60 SMA204.12% SMA507.81% SMA20022.38% Volume934,763 Change0.62%
Mar-04-20Initiated Barclays Overweight $45
Feb-26-20Reiterated Oppenheimer Outperform $32 → $35
Feb-26-20Reiterated H.C. Wainwright Buy $32 → $36
Dec-18-19Initiated JMP Securities Mkt Outperform $38
Oct-01-19Initiated Stifel Buy $27
Apr-29-19Initiated Piper Jaffray Overweight $20
Feb-28-19Reiterated Chardan Capital Markets Buy $30 → $20
Feb-07-19Initiated Robert W. Baird Outperform
Dec-31-18Resumed B. Riley FBR Buy $24
Jul-06-18Reiterated Chardan Capital Markets Buy
Apr-10-18Upgrade B. Riley FBR, Inc. Neutral → Buy $22
Mar-13-18Reiterated B. Riley FBR, Inc. Neutral $18.50 → $22
Feb-23-18Downgrade B. Riley FBR, Inc. Buy → Neutral $18 → $18.50
Jan-25-18Reiterated H.C. Wainwright Buy $16 → $22
Nov-01-17Reiterated B. Riley FBR, Inc. Buy $17.50 → $18
Mar-27-20 02:55PM  Hedge Funds Have Never Been This Bullish On Iovance Biotherapeutics, Inc. (IOVA) Insider Monkey
Mar-11-20 09:18AM  Are Options Traders Betting on a Big Move in Iovance Biotherapeutics (IOVA) Stock? Zacks -7.36%
Mar-10-20 08:23AM  Does Market Volatility Impact Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Share Price? Simply Wall St.
Mar-02-20 04:01PM  Iovance Biotherapeutics to Present at Upcoming Conferences GlobeNewswire +9.36%
Feb-25-20 05:46PM  Report: Peninsula cell therapy company explores sale American City Business Journals +27.42%
04:01PM  Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update GlobeNewswire
Feb-19-20 07:00AM  Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Tuesday, February 25, 2020 GlobeNewswire
Feb-12-20 07:00AM  Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences GlobeNewswire
Jan-15-20 08:00AM  Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel GlobeNewswire
Jan-13-20 04:15PM  Why This Biotech Stock Is Planning To Gene Edit Its Cancer Drugs Investor's Business Daily -11.86%
Jan-12-20 04:30PM  Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog GlobeNewswire
Dec-26-19 11:25AM  How Did Iovance Biotherapeutics, Inc. (IOVA) Perform In Comparison to Hedge Fund Favorites in 2019? Insider Monkey
Dec-23-19 05:40AM  Wall Street Roundup: Analysts Make Moves on These 3 Stocks TipRanks
Dec-16-19 03:55PM  5 Health Care Stocks Gurus Are Buying GuruFocus.com +5.20%
Dec-04-19 08:03PM  Hedge Funds Have Never Been This Bullish On Iovance Biotherapeutics, Inc. (IOVA) Insider Monkey
05:17AM  We Think Iovance Biotherapeutics (NASDAQ:IOVA) Can Afford To Drive Business Growth Simply Wall St.
Dec-02-19 07:00AM  Iovance Biotherapeutics to Present at Upcoming Investor Conferences in December GlobeNewswire
Nov-21-19 07:00AM  Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy GlobeNewswire
Nov-08-19 02:58PM  The Unloved Biotechnology ETF Rally ETF Trends +14.33%
07:00AM  Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer 34th Annual Meeting GlobeNewswire
Nov-07-19 04:32PM  Iovance Biotherapeutics to Present at Upcoming Investor Conferences in November GlobeNewswire
Nov-04-19 04:01PM  Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results GlobeNewswire -6.87%
Oct-31-19 04:43PM  Iovance Biotherapeutics to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Monday, November 4, 2019 GlobeNewswire
Oct-21-19 10:55AM  Hedge Funds Are Dumping Iovance Biotherapeutics, Inc. (IOVA) Insider Monkey
Oct-02-19 07:00AM  Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting GlobeNewswire +6.86%
Oct-01-19 01:48PM  Stifel Bullish On Iovance And Fate Therapeutics, Neutral On Bluebird Bio Benzinga
Sep-27-19 04:30PM  Iovance Biotherapeutics to Present at Upcoming Conferences GlobeNewswire
Sep-19-19 02:07PM  Have Insiders Been Buying Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares This Year? Simply Wall St.
Sep-16-19 12:00PM  Iovance Biotherapeutics: Technical Analysis and Strategy TheStreet.com
Aug-27-19 04:57PM  Iovance Biotherapeutics: Buy the Dip? Motley Fool
Aug-26-19 04:30PM  Iovance Biotherapeutics to Present at Upcoming Investor Conferences in September GlobeNewswire
Aug-14-19 01:04PM  IOVA Stock Could See Another Massive Rebound Schaeffer's Investment Research
Aug-02-19 10:24PM  Iovance Biotherapeutics, Inc. (IOVA) Q2 2019 Earnings Call Transcript Motley Fool -5.76%
04:28PM  Biotech Merger Activity Has Been Hot In 2019 So, What's One More? Investor's Business Daily
Aug-01-19 04:01PM  Iovance Biotherapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-29-19 03:00PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Jul-26-19 07:00AM  Iovance Biotherapeutics to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1, 2019 GlobeNewswire
Jul-18-19 08:00AM  Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein, M.D., as Chief Medical Officer GlobeNewswire +5.31%
Jul-10-19 12:46PM  Does Market Volatility Impact Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Share Price? Simply Wall St.
Jul-08-19 06:22PM  Here's Why Iovance Biotherapeutics Soared 50% in June Motley Fool
Jul-02-19 08:50AM  Iovance stock up 2% after company gives positive regulatory update on potential cervical cancer treatment MarketWatch
07:30AM  Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA) GlobeNewswire
Jun-25-19 09:21AM  3 Stocks With a Perfect Smart Score TipRanks
Jun-24-19 03:00PM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
Jun-19-19 01:58PM  Harry Boxers three biotech stocks on the move include Nektar Therapeutics MarketWatch
Jun-18-19 09:51AM  Cancer Therapy Stocks Soar After Pfizer Deal Investopedia
07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
Jun-17-19 03:37PM  Why Iovance Biotherapeutics Stock Jumped Today Motley Fool +14.92%
Jun-14-19 09:08AM  Did Hedge Funds Drop The Ball On Iovance Biotherapeutics, Inc. (IOVA) ? Insider Monkey
Jun-12-19 10:30AM  PHIO: Two Compounds Entering Clinic in 2020 Zacks Small Cap Research
Jun-11-19 07:00AM  Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors GlobeNewswire -5.02%
Jun-05-19 03:11PM  Cancer-Fighting Stocks & ETF: What You Need to Know Zacks
08:00AM  Iovance and Amgen Are Making Cancer History Bloomberg
Jun-03-19 04:21PM  Why Iovance Biotherapeutics Stock Jumped Today Motley Fool +10.34%
02:46PM  Why Cancer-Fighting Stocks & ETFs Are Soaring Zacks
01:22PM  Oncology Stock Expected to Double (Again) Schaeffer's Investment Research
May-31-19 07:00AM  Updated Results of Studies in Advanced Cervical Cancer and Melanoma Support Long-Term Efficacy of Iovance Tumor Infiltrating Lymphocyte (TIL) Therapy GlobeNewswire -8.30%
06:59AM  Iovance Biotherapeutics to Participate in Upcoming Conferences in June GlobeNewswire
May-29-19 08:00AM  Iovance Biotherapeutics Announces New Facility to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products GlobeNewswire
May-23-19 04:09PM  How This Small Biotech Could Take On Merck In Cervical Cancer Drugs Investor's Business Daily
07:37AM  The Daily Biotech Pulse: Breakthrough Therapy Designation For Iovance, Guardant Prices Offering, 2 Stocks to Debut Benzinga
May-22-19 10:24AM  Implied Volatility Surging for Iovance Biotherapeutics (IOVA) Stock Options Zacks
09:20AM  Investors Who Bought Iovance Biotherapeutics (NASDAQ:IOVA) Shares Three Years Ago Are Now Up 173% Simply Wall St.
May-19-19 09:00AM  3 Biotech Stocks That Soared Last Week: Are They Buys? Motley Fool
May-16-19 04:29PM  Why Snap, Kemet, and Iovance Biotherapeutics Jumped Today Motley Fool +36.06%
04:14PM  Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting Investor's Business Daily
02:47PM  Here's Why Iovance Biotherapeutics Soared Today Motley Fool
12:30PM  Iovance Issues Cancer Trial Updates Ahead Of ASCO Meeting, Sending Stock Skyward Benzinga
07:40AM  The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics Benzinga
May-15-19 05:27PM  Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs GlobeNewswire
May-08-19 05:23AM  Iovance Biotherapeutics, Inc. (IOVA) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 05:13PM  Iovance Biotherapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Iovance Biotherapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
May-03-19 09:01AM  Heres What Hedge Funds Think About Iovance Biotherapeutics, Inc. (IOVA) Insider Monkey
May-02-19 07:00AM  Iovance Biotherapeutics to Participate in Upcoming Conferences in May GlobeNewswire
May-01-19 07:00AM  Iovance Biotherapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on Tuesday, May 7, 2019 GlobeNewswire
Apr-22-19 10:15AM  PHIO: Activation in the Tumor Microenvironment Zacks Small Cap Research
Apr-03-19 04:18PM  Here's Why Iovance Biotherapeutics Soared on Wednesday Motley Fool +20.41%
07:05AM  Iovance Biotherapeutics to Present New Data from Ongoing Studies of Tumor-Infiltrating Lymphocyte (TIL) Therapy at 2019 American Society of Clinical Oncology (ASCO) Meeting GlobeNewswire
07:00AM  Iovance Biotherapeutics Announces Clinical Programs Update GlobeNewswire
Apr-02-19 07:00AM  Iovance Biotherapeutics Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma GlobeNewswire
Apr-01-19 08:00AM  Iovance Biotherapeutics Presents Data at AACR Annual Meeting on T-Cell Diversity and Persistence in Patients Receiving Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel GlobeNewswire
Mar-29-19 08:23AM  Iovance Biotherapeutics Announces April Scientific and Investor Presentations GlobeNewswire
Mar-26-19 11:57AM  Did Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Insiders Buy Up More Shares? Simply Wall St.
Mar-06-19 07:00AM  Iovance Biotherapeutics to Present at Upcoming Investor Conferences in March GlobeNewswire -8.05%
Feb-27-19 08:02PM  Iovance Biotherapeutics, Inc. (IOVA) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Feb-26-19 07:00AM  Iovance Biotherapeutics was Granted Fast Track Designation for LN-145 for Cervical Cancer GlobeNewswire
Feb-22-19 07:00AM  Iovance Biotherapeutics to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call and Webcast on Wednesday, February 27, 2019 GlobeNewswire
Feb-05-19 08:53AM  Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Is Trading At A 49.98% Discount Simply Wall St. -5.19%
Feb-04-19 12:20PM  Stocks Moving After Hours: Seagate, STMicroelectronics, Google, Legg Mason Investing.com +8.21%
Feb-01-19 07:00AM  Iovance Biotherapeutics to Present at Upcoming Investor and Medical Conferences GlobeNewswire
Jan-04-19 09:02AM  2 Promising Biotech Stocks That Insiders Are Snapping Up TheStreet.com +7.20%
Dec-21-18 07:00AM  Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire -7.63%
Dec-14-18 10:00AM  Here's a Handful of Small Biotechs Where Insiders Are Buying TheStreet.com
Dec-12-18 02:28AM  Is Iovance Biotherapeutics, Inc. (IOVA) A Good Stock To Buy? Insider Monkey
Dec-10-18 07:48AM  Insider Buys Of The Week: Iovance, Mohawk, United Continental Benzinga +12.04%
Dec-05-18 09:21AM  What Kind Of Shareholders Own Iovance Biotherapeutics Inc (NASDAQ:IOVA)? Simply Wall St.
Nov-13-18 08:01AM  Iovance Biotherapeutics to Participate at November Investor Conferences GlobeNewswire
Nov-06-18 05:35PM  Iovance Biotherapeutics: 3Q Earnings Snapshot Associated Press -6.88%
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers. The company has research collaboration and clinical grant agreements with Moffitt to evaluate TIL therapy in a clinical trial that combines TIL with nivolumab in NSCLC; strategic alliance agreement with M.D. Anderson Cancer Center to conduct clinical and preclinical research studies; strategic alliance agreement with Roswell Park Cancer Institute to conduct a clinical research study of TIL therapy in bladder cancer; collaboration agreement with MedImmune to conduct clinical and preclinical research in immuno-oncology; preclinical research collaboration with the Ohio State University; and a preclinical research collaboration with Cellectis S.A. to investigate transcription activator-like effector nucleases. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
open in yahoo | open in reuters | open in google